Pivot Pharmaceuticals Inc. PVOTF Archives - Page 3 of 4

WednesdayMay 16, 2018 11:52 am

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) Aims for Rapid Delivery of Cancer, Skin, Female Sexual Dysfunction Therapies

Pivot developing nutraceutical and pharmaceutical therapies based on cannabis derivatives Female sexual dysfunction market expected to exceed booming male products market Skin and oral delivery of Pivot products driven by innovative technologies The advent of modern licensing controls for over-the-counter medications in Canada nearly 15 years ago paved the way for people to pursue health options ranging from traditional Chinese medicines to manufactured vitamins with greater freedom. Caught up in the current were a number of cannabis-based therapies taking advantage of the growing attention paid to the plant’s medicinal properties. Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) is one of…

TuesdayMay 15, 2018 10:13 am

QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Posts Shareholder Update

Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning provided an update to shareholders regarding the current state of the company. Among other highlights, the update included an overview of Pivot’s plans to generate value for the company and shareholders. "As a business, we see a glaring demand for differentiated products and solutions, backed by proven technologies, that match the vast needs of medicinal and recreational consumers outside of the dried flower segment. We will capitalize on this segment of the market and we are working towards building a sustainable, long-term business with the ultimate goal of delivering value…

FridayMay 11, 2018 2:27 pm

QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Leverages Innovative Technologies for Improved Cannabinoid Product Delivery

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) holds significant patents and a cannabinoid product portfolio designed with disruptive technologies that strive to maximize bioavailability, stability and drug release rates. A recent article highlights PVOTF’s innovative delivery technologies, indicating, “Some patents maintain the company’s impetus in making cannabis available through powdered formulations that can be combined with products in the food and beverage market. Through subsidiary Thrudermic (http://ibn.fm/mzYPp), the company is invested in a transdermal lipid-based nano-dispersion technology that enhances skin absorption of cannabinoids, and the company’s water soluble, oral delivery product, PGS-N001, is designed to provide relief to cancer…

WednesdayMay 02, 2018 11:02 am

QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Targets Several Indications with Wide-ranging Product Pipeline

Vancouver-based biopharmaceutical company Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) that currently has numerous pharmaceutical and nutraceutical products in its development pipeline. An article discussing the company reads: “Pivot has a number of products in its pipeline that are in various stages of development. These target therapies for pain, inflammation, dermatology, eye disease and cancer supportive care. PGS-N005 is a cannabidiol (CBD)-based topical cream to treat female sexual dysfunction, a disorder that is estimated to affect up to 63 percent of women in the United States (http://ibn.fm/MOhVG). The market for female sexual dysfunction disorder therapies is estimated to be…

MondayApr 23, 2018 12:21 pm

QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Holds Promising Position in Expanding Cannabis Space

With its proven pharmaceutical and patented formulation and delivery technologies, Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) holds a favorable position in an expanding vertical of the cannabis industry. An article discussing the company reads: “Pivot Pharmaceuticals has assembled cutting-edge drug delivery technologies that assist both effectiveness and efficacy of medicinal cannabinoids and have potential applications across other drug categories. Pivot’s patent pending topical transdermal drug delivery technology platform, BiPhasix™, has been shown to significantly enhance the bioavailability of various drugs, leading to improved clinical outcomes. The company also acquired worldwide rights to Solmic Solubilisation…

MondayApr 16, 2018 10:28 am

QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Terminates LOI for the Acquisition of Agro-Biotech

Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning reported that it has terminated the previously announced letter of intent (“LOI”) that it had entered into for the acquisition of Agro-Biotech. The company is currently reviewing its available legal alternatives to recover the amounts expended by the company in the pursuit of the transaction, as well as additional damages resulting from the non-completion of the transaction. "Despite our extensive efforts, we have been unable to complete the acquisition of Agro-Biotech in accordance with the terms and conditions initially agreed upon by the parties. While we…

FridayApr 13, 2018 3:35 pm

QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Entering Multi-billion-dollar Industries through Strategic Acquisitions

Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) is developing disruptive formulations for cannabis-infused markets. An article discussing the company reads: “Pivot’s acquisition of California’s ERS Holdings, LLC in February not only strengthened its options for enhanced health and wellness products; the move gave the company added visibility to beverage makers such as beer companies working to mitigate a potential decline in profits as their customers divert discretionary income from alcohol consumption to cannabis consumption. … “The (Ready-To-Infuse-Cannabis technology) family of patents will be transformational for the food and beverage industry. Based on our interaction with…

WednesdayApr 11, 2018 1:54 pm

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Provides Update on Bio-Cannabis Product Pipeline

Several proprietary products developed and ready to market in Canada, California and global markets Cannabis product sales expected to generate significant revenue Pivot’s IP portfolio includes global patents to cement its leading position in the cannabis industry On April 4, 2018, Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) published an update on the advancements of its industry-leading cannabis product pipeline (http://ibn.fm/leP8x). A newly developed 1% cannabidiol (CBD) oral micelle solution, created in collaboration with the company’s German technology partner, Solmic GmbH, is ready to market. The development of two topical creams using Pivot’s patented formulation and delivery systems is…

FridayApr 06, 2018 2:15 pm

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Extracts Maximum Benefit from Cannabis Portfolio

Forecasts predict $55.8 billion valuation for medical cannabis market by 2025 Pivot Pharmaceuticals building portfolio of diverse tech for improving bioavailability of cannabinoid therapies Company’s leadership team builds on decades of experience in pharmaceutical arena For nutrition-conscious consumers, scanning food product labels is a requisite part of any trip to the grocery store, but a recent study by the U.S. Department of Agriculture’s Agricultural Research Service (http://ibn.fm/727E5) found that the old maxim ‘what you see isn’t always what you get’ holds true when it comes to certain foods like nuts. Even though pistachios, for example, may have 161.9 calories per ounce, only…

WednesdayApr 04, 2018 9:26 am

QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Posts Product Development Update

Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning issued a corporate update regarding the progress of its bio-cannabis product pipeline. Per the update, a 1% CBD Oral Micelle Solution developed in Germany is set to market and the company has completed development of two topical creams that employ its patented formulation and delivery systems. Pivot anticipates that it will have numerous products available for sale in Canada on the date legalization officially begins. The company also expects to begin sales in California as of the third quarter 2018, including the launch of its proprietary…

Site Search

Company Search

Tag: Pivot Pharmaceuticals Inc. PVOTF